DIFFERENTIAL-EFFECTS OF FOSINOPRIL AND ENALAPRIL IN PATIENTS WITH MILD-TO-MODERATE CHRONIC HEART-FAILURE

Objectives To investigate the efficacy and safety of fosinopril in the treatment of chronic heart failure (CHF), patients with mild to moder ate CHF and left ventricular ejection fractions <40% were randomly ass igned in a double-blind manner to receive fosinopril 5 to 20 mg every day (n = 122) or enalapril 5 to 20 mg every day (n = 132) For 1 year. Results The event-free survival time was longer (1.6 vs 1.0 months, P = .032) and the total rate of hospitalizations plus deaths was smaller with fosinopril than with enalapril (19.7% vs 25.0%, P = .028). There was consistently better symptom improvement with fosinopril (P < .05) , The incidence of orthostatic hypotension was lower in the fosinopril group (1.6 % vs 7.6 %, P < .05). Conclusions Fosinopril 5 to 20 mg ev ery day was more effective in improving symptoms and delaying events r elated to worsening of CHF and produced less orthostatic hypotension t han enalapril 5 to 20 mg every day.